RU2009136303A - Пероральное введение кальцитонина - Google Patents
Пероральное введение кальцитонина Download PDFInfo
- Publication number
- RU2009136303A RU2009136303A RU2009136303/15A RU2009136303A RU2009136303A RU 2009136303 A RU2009136303 A RU 2009136303A RU 2009136303/15 A RU2009136303/15 A RU 2009136303/15A RU 2009136303 A RU2009136303 A RU 2009136303A RU 2009136303 A RU2009136303 A RU 2009136303A
- Authority
- RU
- Russia
- Prior art keywords
- calcitonin
- amount
- acid
- hydroxybenzoyl
- liquid
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title claims abstract 14
- 108060001064 Calcitonin Proteins 0.000 title claims abstract 14
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims abstract 14
- 229960004015 calcitonin Drugs 0.000 title claims abstract 14
- 238000000034 method Methods 0.000 claims abstract 20
- 239000007788 liquid Substances 0.000 claims abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 8
- 229940124447 delivery agent Drugs 0.000 claims abstract 5
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 claims 9
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 235000012054 meals Nutrition 0.000 claims 5
- CBEKBPBDTOIYKJ-UHFFFAOYSA-N 2-amino-11-(2-hydroxyphenyl)-11-oxoundecanoic acid Chemical compound OC(=O)C(N)CCCCCCCCC(=O)C1=CC=CC=C1O CBEKBPBDTOIYKJ-UHFFFAOYSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 claims 3
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 235000021152 breakfast Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89259407P | 2007-03-02 | 2007-03-02 | |
| US60/892,594 | 2007-03-02 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013150659/15A Division RU2013150659A (ru) | 2007-03-02 | 2013-11-13 | Пероральное введение кальцитонина |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009136303A true RU2009136303A (ru) | 2011-04-10 |
Family
ID=39496395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009136303/15A RU2009136303A (ru) | 2007-03-02 | 2008-02-29 | Пероральное введение кальцитонина |
| RU2013150659/15A RU2013150659A (ru) | 2007-03-02 | 2013-11-13 | Пероральное введение кальцитонина |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013150659/15A RU2013150659A (ru) | 2007-03-02 | 2013-11-13 | Пероральное введение кальцитонина |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8410052B2 (https=) |
| EP (1) | EP2131810B1 (https=) |
| JP (1) | JP5249246B2 (https=) |
| KR (2) | KR20150091536A (https=) |
| CN (2) | CN101621991A (https=) |
| AT (1) | ATE507818T1 (https=) |
| AU (1) | AU2008223108B2 (https=) |
| BR (1) | BRPI0808517A2 (https=) |
| CA (1) | CA2679782C (https=) |
| DE (1) | DE602008006700D1 (https=) |
| ES (1) | ES2365648T3 (https=) |
| MX (1) | MX2009009243A (https=) |
| PL (1) | PL2131810T3 (https=) |
| PT (1) | PT2131810E (https=) |
| RU (2) | RU2009136303A (https=) |
| WO (1) | WO2008109385A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| EP2758057B1 (en) * | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| HRP20181447T1 (hr) | 2012-03-22 | 2018-11-02 | Novo Nordisk A/S | Pripravci glp-1 peptida i njihova priprava |
| PT2827845T (pt) | 2012-03-22 | 2019-03-29 | Novo Nordisk As | Composições compreendendo um agente de entrega e sua preparação |
| ES2965469T3 (es) | 2012-03-22 | 2024-04-15 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y preparación de estas |
| JP6517690B2 (ja) * | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| KR102272671B1 (ko) | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| IL297415A (en) * | 2020-04-22 | 2022-12-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Active phenolate salt complex |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| WO2000059480A1 (en) | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| ES2235854T3 (es) * | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| KR20040030120A (ko) * | 2001-08-17 | 2004-04-08 | 노파르티스 아게 | 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TWI307279B (en) | 2002-08-01 | 2009-03-11 | Novartis Ag | Oral administration of calcitonin |
| ES2398237T3 (es) * | 2003-07-23 | 2013-03-14 | Novartis Ag | Uso de calcitonina en osteoartritis |
-
2008
- 2008-02-29 CN CN200880006790A patent/CN101621991A/zh active Pending
- 2008-02-29 CA CA2679782A patent/CA2679782C/en not_active Expired - Fee Related
- 2008-02-29 MX MX2009009243A patent/MX2009009243A/es active IP Right Grant
- 2008-02-29 PT PT08743617T patent/PT2131810E/pt unknown
- 2008-02-29 ES ES08743617T patent/ES2365648T3/es active Active
- 2008-02-29 EP EP08743617A patent/EP2131810B1/en not_active Not-in-force
- 2008-02-29 KR KR1020157020307A patent/KR20150091536A/ko not_active Ceased
- 2008-02-29 PL PL08743617T patent/PL2131810T3/pl unknown
- 2008-02-29 US US12/529,371 patent/US8410052B2/en not_active Expired - Fee Related
- 2008-02-29 CN CN201710436918.4A patent/CN107050433A/zh active Pending
- 2008-02-29 RU RU2009136303/15A patent/RU2009136303A/ru unknown
- 2008-02-29 AU AU2008223108A patent/AU2008223108B2/en not_active Ceased
- 2008-02-29 WO PCT/US2008/055399 patent/WO2008109385A2/en not_active Ceased
- 2008-02-29 BR BRPI0808517-0A patent/BRPI0808517A2/pt not_active IP Right Cessation
- 2008-02-29 DE DE602008006700T patent/DE602008006700D1/de active Active
- 2008-02-29 JP JP2009551864A patent/JP5249246B2/ja not_active Expired - Fee Related
- 2008-02-29 KR KR1020097018236A patent/KR101564114B1/ko not_active Expired - Fee Related
- 2008-02-29 AT AT08743617T patent/ATE507818T1/de active
-
2013
- 2013-11-13 RU RU2013150659/15A patent/RU2013150659A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008223108A2 (en) | 2009-09-10 |
| AU2008223108A1 (en) | 2008-09-12 |
| MX2009009243A (es) | 2009-09-08 |
| US8410052B2 (en) | 2013-04-02 |
| DE602008006700D1 (https=) | 2011-06-16 |
| CN101621991A (zh) | 2010-01-06 |
| RU2013150659A (ru) | 2015-05-20 |
| WO2008109385A3 (en) | 2009-04-09 |
| CA2679782C (en) | 2015-02-17 |
| EP2131810B1 (en) | 2011-05-04 |
| WO2008109385A2 (en) | 2008-09-12 |
| BRPI0808517A2 (pt) | 2014-08-19 |
| US20100210526A1 (en) | 2010-08-19 |
| ATE507818T1 (de) | 2011-05-15 |
| CA2679782A1 (en) | 2008-09-12 |
| KR20150091536A (ko) | 2015-08-11 |
| PL2131810T3 (pl) | 2011-09-30 |
| EP2131810A2 (en) | 2009-12-16 |
| CN107050433A (zh) | 2017-08-18 |
| JP2010520221A (ja) | 2010-06-10 |
| ES2365648T3 (es) | 2011-10-07 |
| AU2008223108B2 (en) | 2013-10-10 |
| KR20090116772A (ko) | 2009-11-11 |
| KR101564114B1 (ko) | 2015-10-28 |
| JP5249246B2 (ja) | 2013-07-31 |
| PT2131810E (pt) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013150659A (ru) | Пероральное введение кальцитонина | |
| RU2009111391A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
| Grimble | Adverse gastrointestinal effects of arginine and related amino acids | |
| AU605154B2 (en) | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | |
| ES2443817T3 (es) | Método para tratar la deficiencia de vitamina B12 | |
| ES2393933T3 (es) | Conjugados que comprenden un fármaco psicotrópico o un agonista GABA y un ácido orgánico y su uso para el tratamiento del dolor y otros transtornos del SNC | |
| ES2436152T3 (es) | Uso de calcitonina en osteoartritis | |
| RU2600440C3 (ru) | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| JP2019517555A (ja) | Ｐｉが５．８〜８．５間の少なくとも１つの基礎インスリン、プランディアルインスリン及び／又は消化管ホルモン、及び、カルボン酸塩電荷と疎水性基を有するコポリアミノ酸を含むｐｈ７の注射剤 | |
| NO20060329L (no) | Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse | |
| BR112013031268B1 (pt) | Polipeptídeos | |
| CA2420590A1 (en) | Active agent delivery systems and methods for protecting and administering active agents | |
| ATE345810T1 (de) | Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide | |
| JP2009534323A5 (https=) | ||
| SI3068796T1 (en) | Calcitonin mimetics for the treatment of diseases and disorders | |
| JP2006522821A5 (https=) | ||
| CN101605538A (zh) | 瓜氨酸用于治疗营养缺乏状况的用途 | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| AU2002333443C1 (en) | 5-CNAC as oral delivery agent for parathyroid hormone fragments | |
| JP2011026348A5 (https=) | ||
| US20090306209A1 (en) | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same | |
| ES2547379T3 (es) | Utilización de calcitonina para el tratamiento de la AR | |
| CN121358489A (zh) | 具有改善特性的类似物 | |
| RU2005105691A (ru) | Пероральное введение кальцитонина |